Teva announces post hoc analysis of long-term data examining treatment with austedo® (deutetrabenazine) tablets in adult patients with tardive dyskinesia

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced results from a post hoc analysis of a long-term, 3-year open-label extension (ole) study examining efficacy and safety endpoints for the use of austedo (deutetrabenazine) tablets in younger (
TEVA Ratings Summary
TEVA Quant Ranking